ConductScience.org, home

Paper16601286

Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma.

Fung KM and 12 others. Endocr Relat Cancer, 2006. Cited by 116 papers, by iCite.

Cite this record

ConductScience Library. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Papers, record 16601286. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/16601286

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma.
PubMed
Journal
Endocr Relat Cancer
PubMed
Year
2006
PubMed
Publication types
Comparative Study, Journal Article, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
116
iCite
Relative citation ratio, by iCite
3.04
iCite
Revised in PubMed
2017-11-16
PubMed

Authors13

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Fung KMK-M
2Samara ENE N S
3Wong CC
4Metwalli AA
5Krlin RR
6Bane BB
7Liu CZC Z
8Yang JTJ T
9Pitha JVJ V
10Culkin DJD J
11Kropp BPB P
12Penning TMT M
13Lin HKHsueh-Kung

Source PubMed

Download CSV of authors

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
3-Hydroxysteroid DehydrogenasesMajor topic
AdenocarcinomaMajor topic
Hydroxyprostaglandin DehydrogenasesMajor topic
ProstateMajor topic
Prostatic NeoplasmsMajor topic
Receptors, AndrogenMajor topic
Aged
Aldo-Keto Reductase Family 1 Member C3
Antibodies, Monoclonal
Blotting, Western
Epithelial Cells
Gene Expression Regulation, Enzymologic
Humans
Immunoenzyme Techniques
Male
Middle Aged
Reverse Transcriptase Polymerase Chain Reaction
Stromal Cells
Tumor Cells, Cultured

Source PubMed

Download CSV of topics

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
CA 97044NCI NIH HHSUnited StatesPubMedPubMed
DK 47015NIDDK NIH HHSUnited StatesR01DK047015PubMed and NIHNIH RePORTER
DK 54925NIDDK NIH HHSUnited StatesR01DK054925PubMed and NIHNIH RePORTER

Download CSV of grants

Cited by59

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 116 citations.

PMIDTitleJournalYearIn PapersSource
42390142Phase 2 dose-expansion trial of OBI-3424, a DNA-alkylating prodrug, in patients with advanced solid tumors expressing AKR1C3.Oncologist2026https://conductscience.org/library/papers/42390142PubMed
40127205Inhibition of Steroidogenesis in Prostate Cancer Cells by Both a Natural and Another Synthetic Steroid.Drug Dev Res2025https://conductscience.org/library/papers/40127205PubMed
38421088Activation of testosterone-androgen receptor mediates cerebrovascular protection by photobiomodulation treatment in photothrombosis-induced stroke rats.CNS Neurosci Ther2024https://conductscience.org/library/papers/38421088PubMed
37900995Prostaglandin F2α synthase promotes oxaliplatin resistance in colorectal cancer through prostaglandin F2α-dependent and F2α-independent mechanism.World J Gastroenterol2023https://conductscience.org/library/papers/37900995PubMed
37428858Aldo-Keto Reductase 1C3 Inhibitor Prodrug Improves Pharmacokinetic Profile and Demonstrates In Vivo Efficacy in a Prostate Cancer Xenograft Model.J Med Chem2023https://conductscience.org/library/papers/37428858PubMed
36845727A novel ferroptosis-related gene signature for predicting prognosis in multiple myeloma.Front Oncol2023https://conductscience.org/library/papers/36845727PubMed
31672619The role of adrenal derived androgens in castration resistant prostate cancer.J Steroid Biochem Mol Biol2020https://conductscience.org/library/papers/31672619PubMed
31052459Consecutive Prostate Cancer Specimens Revealed Increased Aldo⁻Keto Reductase Family 1 Member C3 Expression with Progression to Castration-Resistant Prostate Cancer.J Clin Med2019https://conductscience.org/library/papers/31052459PubMed
31015346OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL.Clin Cancer Res2019https://conductscience.org/library/papers/31015346PubMed
30241348Characterization of Precursor-Dependent Steroidogenesis in Human Prostate Cancer Models.Cancers (Basel)2018https://conductscience.org/library/papers/30241348PubMed
30137266Structural and Functional Biology of Aldo-Keto Reductase Steroid-Transforming Enzymes.Endocr Rev2019https://conductscience.org/library/papers/30137266PubMed
30012349AKR1C3 (type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase): Roles in malignancy and endocrine disorders.Mol Cell Endocrinol2019https://conductscience.org/library/papers/30012349PubMed
28865807Intracrine androgen biosynthesis, metabolism and action revisited.Mol Cell Endocrinol2018https://conductscience.org/library/papers/28865807PubMed
28367977Riboflavin deficiency induces a significant change in proteomic profiles in HepG2 cells.Sci Rep2017https://conductscience.org/library/papers/28367977PubMed
27486833Discovery of (R)-2-(6-Methoxynaphthalen-2-yl)butanoic Acid as a Potent and Selective Aldo-keto Reductase 1C3 Inhibitor.J Med Chem2016https://conductscience.org/library/papers/27486833PubMed
26797685Classical and Non-Classical Roles for Pre-Receptor Control of DHT Metabolism in Prostate Cancer Progression.Horm Cancer2016https://conductscience.org/library/papers/26797685PubMed
26429394Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells.J Steroid Biochem Mol Biol2016https://conductscience.org/library/papers/26429394PubMed
26116659AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia.Blood2015https://conductscience.org/library/papers/26116659PubMed
26032458Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC).J Steroid Biochem Mol Biol2015https://conductscience.org/library/papers/26032458PubMed
25379460Steroid hormone synthetic pathways in prostate cancer.Transl Androl Urol2013https://conductscience.org/library/papers/25379460PubMed

See all 59 cited byDownload CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AKR1C38644PubTator's text mininghttps://conductscience.org/library/genes/8644NCBI Gene
AKR1C41109PubTator's text mininghttps://conductscience.org/library/genes/1109NCBI Gene
AR367PubTator's text mininghttps://conductscience.org/library/genes/367NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/16601286

GET https://conductscience.org/api/papers/v1/16601286/cited_by?page=2